Lena M Biehl1, Martin Schmidt-Hieber2, Blasius Liss1, Oliver A Cornely1,3,4, Maria J G T Vehreschild1,3. 1. a 1st Department of Internal Medicine , University of Cologne , Cologne , Germany . 2. b Klinik für Hämatologie, Onkologie und Tumorimmunologie , HELIOS Klinikum Berlin Buch , Berlin , Germany . 3. c German Centre for Infection Research at Cologne , Germany , and. 4. d Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, and Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne , Cologne , Germany.
Abstract
BACKGROUND: The prevalence of extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E) is increasing worldwide. ESBL-E are known to colonize different body sites and cause bloodstream infections (BSI), pneumonia, intra-abdominal infections and urinary tract infections. Even though ESBL-E-related morbidity and mortality in high-risk patients - patients receiving immunosuppressants or chemotherapy, as well as those treated in an ICU - is considerable, the management of ESBL-E in these populations has not been systematically reviewed. METHODS: For the purpose of this review, ICU patients, patients in hematology and oncology wards and transplant recipients were considered high-risk. An English-language Medline search was conducted to identify literature on epidemiology, risk factors, clinical impact and measures of infection control regarding ESBL-E in high-risk patients published between June 2002 and May 2013. RESULTS: Using the above described methodology, 43 relevant articles regarding high-risk patients and - for areas where literature on exclusively high-risk patients is scarce - 17 articles in standard risk settings were identified. The evidence on epidemiology, associated risk factors, treatment and hygiene measures were summarized. DISCUSSION: This review gives a complete overview on the management of ESBL-E in the high-risk setting.
BACKGROUND: The prevalence of extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E) is increasing worldwide. ESBL-E are known to colonize different body sites and cause bloodstream infections (BSI), pneumonia, intra-abdominal infections and urinary tract infections. Even though ESBL-E-related morbidity and mortality in high-risk patients - patients receiving immunosuppressants or chemotherapy, as well as those treated in an ICU - is considerable, the management of ESBL-E in these populations has not been systematically reviewed. METHODS: For the purpose of this review, ICU patients, patients in hematology and oncology wards and transplant recipients were considered high-risk. An English-language Medline search was conducted to identify literature on epidemiology, risk factors, clinical impact and measures of infection control regarding ESBL-E in high-risk patients published between June 2002 and May 2013. RESULTS: Using the above described methodology, 43 relevant articles regarding high-risk patients and - for areas where literature on exclusively high-risk patients is scarce - 17 articles in standard risk settings were identified. The evidence on epidemiology, associated risk factors, treatment and hygiene measures were summarized. DISCUSSION: This review gives a complete overview on the management of ESBL-E in the high-risk setting.
Authors: Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton Journal: Antimicrob Agents Chemother Date: 2015-02-02 Impact factor: 5.191
Authors: Mariana Castanheira; Leonard R Duncan; Rodrigo E Mendes; Helio S Sader; Dee Shortridge Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: A Tratselas; M Simitsopoulou; A Giannakopoulou; I Dori; S Saoulidis; K Kollios; P Papaioannidou; S Pournaras; E Roilides Journal: Antimicrob Agents Chemother Date: 2014-09-15 Impact factor: 5.191
Authors: H M Abdallah; B B Wintermans; E A Reuland; A Koek; N al Naiemi; A M Ammar; A A Mohamed; C M J E Vandenbroucke-Grauls Journal: PLoS One Date: 2015-05-22 Impact factor: 3.240
Authors: Cédric Dananché; Thomas Bénet; Bernard Allaouchiche; Romain Hernu; Laurent Argaud; Olivier Dauwalder; François Vandenesch; Philippe Vanhems Journal: Crit Care Date: 2015-02-10 Impact factor: 9.097
Authors: Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer Journal: Ann Hematol Date: 2016-06-24 Impact factor: 3.673